NICE says no to Takeda's Mepact
This article was originally published in Scrip
NICE, the health technology institute for England and Wales, has again said it will not be recommending Takeda's Mepact (mifamurtide) for young bone cancer patients because of the drug's high cost and uncertainty over how much extra benefit the drug offers compared with current treatment.
You may also be interested in...
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.